skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: MO-FG-CAMPUS-TeP2-02: First Experiences and Perspectives in Using Direct Multicriteria Optimization (MCO) On Volumetric-Modulated Arc Therapy (VMAT) for Head and Neck Cancer

Abstract

Purpose: To report the first experiences and perspectives in using direct multicriteria optimization (MCO) on volumetric-modulated arc therapy (VMAT) for head and neck (H&N) cancer. Methods: Ten prior patients with tumors in representative H&N regions were selected to evaluate direct MCO-VMAT in RayStation v5.0 beta. The patients were previously treated by intensity-modulated radiation therapy (IMRT) with MCO on an Elekta linear accelerator with Agility multileaf collimator. To avoid radiating eyes and shoulders, MCO-VMAT required one to three partial-arc groups, with each group consisting of single or dual arcs. All MCO-VMAT plans were approved by a radiation oncologist. The MCO-VMAT and MCO-IMRT plans were compared using V{sub 100}, D{sub 5}, homogeneity index (HI) and conformity index (CI) for planning target volume (PTV), D{sub mean} and D{sub 50} for six parallel organs and D{sub max} for five serial organs. Patient-specific quality assurance (QA) was performed using ArcCHECK for MCO-VMAT and Matrixx for MCO-IMRT with results analyzed using gamma criteria of 3%/3mm. Results: MCO-VMAT provided better V{sub 100} (+0.8%) lower D{sub 5}(− 0.3 Gy), lower HI (−0.27) and comparable CI (+0.05). MCO-VMAT decreased D{sub mean} and D{sub 50} for multiple parallel organs in seven of the ten patients. On average the reduction rangedmore » from 2.1 (larynx) to 7.6 Gy (esophagus). For the nasal cavity and nasopharynx plans significant reduction in D{sub max} was observed for optics (up to 11 Gy) brainstem (6.4 Gy), cord (2.1 Gy) and mandible (6.7 Gy). All MCO-VMAT and -IMRT plans passed clinical QA. MCO-VMAT required slightly longer planning time due to the more complex VMAT optimization. The net beam-on time for the MCO-VMAT plans ranged from 80 to 242 seconds, up to 9 minutes shorter than MCO-IMRT. Conclusion: With similar target coverage, reduced organ dose, comparable planning time, and significantly faster treatment, MCO-VMAT is very likely to become the modality of choice in RayStation v5.0 for H&N cancer.« less

Authors:
; ; ; ;  [1]
  1. Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (United States)
Publication Date:
OSTI Identifier:
22653906
Resource Type:
Journal Article
Resource Relation:
Journal Name: Medical Physics; Journal Volume: 43; Journal Issue: 6; Other Information: (c) 2016 American Association of Physicists in Medicine; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; 61 RADIATION PROTECTION AND DOSIMETRY; LINEAR ACCELERATORS; MEDICAL PERSONNEL; NECK; NEOPLASMS; OPTIMIZATION; PATIENTS; PLANNING; QUALITY ASSURANCE; RADIOTHERAPY

Citation Formats

Edgington, Samantha, Cotter, Christopher, Busse, Paul, Crawford, Bruce, and Wang, Yi. MO-FG-CAMPUS-TeP2-02: First Experiences and Perspectives in Using Direct Multicriteria Optimization (MCO) On Volumetric-Modulated Arc Therapy (VMAT) for Head and Neck Cancer. United States: N. p., 2016. Web. doi:10.1118/1.4957360.
Edgington, Samantha, Cotter, Christopher, Busse, Paul, Crawford, Bruce, & Wang, Yi. MO-FG-CAMPUS-TeP2-02: First Experiences and Perspectives in Using Direct Multicriteria Optimization (MCO) On Volumetric-Modulated Arc Therapy (VMAT) for Head and Neck Cancer. United States. doi:10.1118/1.4957360.
Edgington, Samantha, Cotter, Christopher, Busse, Paul, Crawford, Bruce, and Wang, Yi. Wed . "MO-FG-CAMPUS-TeP2-02: First Experiences and Perspectives in Using Direct Multicriteria Optimization (MCO) On Volumetric-Modulated Arc Therapy (VMAT) for Head and Neck Cancer". United States. doi:10.1118/1.4957360.
@article{osti_22653906,
title = {MO-FG-CAMPUS-TeP2-02: First Experiences and Perspectives in Using Direct Multicriteria Optimization (MCO) On Volumetric-Modulated Arc Therapy (VMAT) for Head and Neck Cancer},
author = {Edgington, Samantha and Cotter, Christopher and Busse, Paul and Crawford, Bruce and Wang, Yi},
abstractNote = {Purpose: To report the first experiences and perspectives in using direct multicriteria optimization (MCO) on volumetric-modulated arc therapy (VMAT) for head and neck (H&N) cancer. Methods: Ten prior patients with tumors in representative H&N regions were selected to evaluate direct MCO-VMAT in RayStation v5.0 beta. The patients were previously treated by intensity-modulated radiation therapy (IMRT) with MCO on an Elekta linear accelerator with Agility multileaf collimator. To avoid radiating eyes and shoulders, MCO-VMAT required one to three partial-arc groups, with each group consisting of single or dual arcs. All MCO-VMAT plans were approved by a radiation oncologist. The MCO-VMAT and MCO-IMRT plans were compared using V{sub 100}, D{sub 5}, homogeneity index (HI) and conformity index (CI) for planning target volume (PTV), D{sub mean} and D{sub 50} for six parallel organs and D{sub max} for five serial organs. Patient-specific quality assurance (QA) was performed using ArcCHECK for MCO-VMAT and Matrixx for MCO-IMRT with results analyzed using gamma criteria of 3%/3mm. Results: MCO-VMAT provided better V{sub 100} (+0.8%) lower D{sub 5}(− 0.3 Gy), lower HI (−0.27) and comparable CI (+0.05). MCO-VMAT decreased D{sub mean} and D{sub 50} for multiple parallel organs in seven of the ten patients. On average the reduction ranged from 2.1 (larynx) to 7.6 Gy (esophagus). For the nasal cavity and nasopharynx plans significant reduction in D{sub max} was observed for optics (up to 11 Gy) brainstem (6.4 Gy), cord (2.1 Gy) and mandible (6.7 Gy). All MCO-VMAT and -IMRT plans passed clinical QA. MCO-VMAT required slightly longer planning time due to the more complex VMAT optimization. The net beam-on time for the MCO-VMAT plans ranged from 80 to 242 seconds, up to 9 minutes shorter than MCO-IMRT. Conclusion: With similar target coverage, reduced organ dose, comparable planning time, and significantly faster treatment, MCO-VMAT is very likely to become the modality of choice in RayStation v5.0 for H&N cancer.},
doi = {10.1118/1.4957360},
journal = {Medical Physics},
number = 6,
volume = 43,
place = {United States},
year = {Wed Jun 15 00:00:00 EDT 2016},
month = {Wed Jun 15 00:00:00 EDT 2016}
}